BTOG relies solely on income from exhibition/sponsorship at education events and annual conference registration fees to allow it to support and educate thoracic oncology health care professionals and to undertake key activities under our three strategic arms – education, research and representation. Sponsorship does not constitute endorsement, recommendation, or favouring by BTOG.

Diamond Sponsor for 2021

For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world. For more information about our products and to register with MSD Connect, visit (this link will direct you to an MSD promotional website). For more information about MSD, visit and connect with us @MSDintheUK on Twitter, Instagram, LinkedIn, YouTube and Facebook.

Platinum Sponsors for 2021

For Amgen, the key to serving patients is by being the best possible partner to the NHS and the professionals that fuel it.  Over the last 40 years, Amgen has developed innovative medicines in cancer and long-term conditions and is immensely proud of the difference made to the lives of people in the UK through these and the services we deliver alongside them, enabling even more value for the system and patients. Committed to driving sustainable solutions that can adapt to an ever-evolving health system, Amgen is proud to serve its people, customers, and patients every day.

Bayer plc aims to develop products that improve people’s quality of life. We concentrate on the research and development of innovative drugs and novel therapeutic approaches to prioritise targets and pathways with the potential to impact not just the treatment of common cancers, but rarer cancers as well.  UK healthcare professionals and other relevant UK decision makers can register here to subscribe to electronic communications about Bayer's products, services and events:   Visit for more information.

At TAKEDA ONCOLOGY, we endeavour to deliver novel medicines to patients with cancer worldwide through our commitment to science, innovation and passion for improving the lives of patients.  We’ve made great strides in our fight against cancer but we are determined to do more. We continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the innovators in oncology that we are today.  We know that our mission is not a quick or simple one, but we are up for the task: we aspire to cure cancer.

Gold Sponsors for 2021

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.  With its global headquarters in Cambridge, AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, we undertook 201 trials in the UK, involving 376 centres and over 7,000 patients. For more information, please visit and follow us on Twitter at @AstraZenecaUK

Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. We are focused on helping patients in disease areas including oncology, cardiovascular, immunoscience and fibrosis. Each day, our employees work together for patients.

Boehringer Ingelheim

Chugai Pharma UK Ltd is a research-based pharmaceutical company, part of the Roche group. Our mission is to provide innovative medical products and services, for the benefit of the UK medical community and the patients in its care.   Chugai is a Japanese global company, with a rich history and strong position in a number of therapeutic areas including: oncology, haematology and rheumatology, and a growing research pipeline including novel targeted therapies and supportive care agents. Chugai’s European Business Development Team also actively seeks new partners to in-licence and commercialise products through our experienced cross functional team.  Chugai is committed to the highest ethical and moral standards in order to fulfil its corporate social responsibility to society.

Creating Medicines to Make Lives Better - Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: "Take what you find here and make it better and better." More than 140 years later, we remain committed to his vision through every aspect of our business and the people we serve starting with those who take our medicines, and extending to health care professionals, employees and the communities in which we live. Lilly’s purpose unites caring with discovery to create medicines that make life better for people around the world.



Silver Sponsors for 2021

Veye Chest is an AI solution for lung nodule management on chest CT. It detects, classifies, and tracks the growth of pulmonary nodules as small as 3 mm. Veye Chest delivers its analysis directly into the radiology workflow, as part of the original PACS study. The solution is CE-marked as a class IIb medical device and can be used as a second or concurrent reader. Veye Lung Nodules is CE certified as a class IIb medical device under the new EU Medical Device Regulation.  Veye Chest is currently running in routine practice and lung cancer screening programmes across Europe.

BeiGene are advancing a pipeline of novel anti-cancer agents and combination solutions aimed to have meaningful, lasting impacts on cancer patients. We have three internally-developed late-stage assets, five marketed products in China and one marketed product in the U.S. In solid tumours such as NSCLC, immune checkpoint inhibitors have shown to benefit when combined with chemotherapy. Our anti–PD-1 antibody tislelizumab is marketed in 1L NSCLC in China and is under evaluation in global Phase 3 trials in NSCLC and SCLC. Our Anti-TIGIT antibody ociperlimab is currently in a Phase 3 study in combination with tislelizumab in 1L, PD-L1-Selected NSCLC.

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics.

Irwin Mitchell - We’re one of the largest law firms in the country, and our experience helps us recover millions of pounds for our clients every year. We have more specialists accredited by the Association of Personal Injury Lawyers (APIL) than any other law firm. A mesothelioma diagnosis is life-changing, and our experts understand the impact it will have on you and your family. Our focus is on getting our clients the support they need and the justice they deserve. We have experts throughout the UK ready to help you and your loved ones get the answers you’re searching for.

T: 0800 023 2233 Website:  Twitter: @IrwinMitchell

Leigh Day Lawyers - Our team has a formidable reputation in asbestos litigation as a consequence of representing victims for over 30 years in the UK and abroad. Our clients keep 100% of their compensation.  Our team has achieved the highest compensation awards for pain, suffering and care for mesothelioma victims. We have protected the rights of victims of asbestos related diseases through Judicial Review and Supreme Court cases whilst representing the Asbestos Victims Support Group Forum UK.   Read about some of them on our website. Our lawyers raise funds for asbestos charities throughout the UK. We deal with cases quickly and aim to obtain compensation for our clients within 3-6 months.

Novartis - In the UK, we employ approximately 1,300 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis. Since 2014, Novartis has invested over £200 million in R&D and is the single largest industry sponsor of clinical trials in the UK. For more information, please visit

Bronze Sponsors for 2021

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD has 65,000 employees and a presence in virtually every country around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Fieldfisher is one of the UK's foremost mesothelioma claims practices. We are renowned for our success and commitment in the pursuit of asbestos andmesothelioma claims. Our team act on a 'no win, no fee' basis. Our specialist solicitors will always visit clients at home, regardless of their location. We are ranked as one of the leading practices in Chambers and Partners 2020, who describe us as a "Market-leading industrial disease practice with an outstanding reputation for undertaking mesothelioma and asbestos disease litigation."

The team of Specialist Asbestos Solicitors at Hugh James represents individuals and their families who are suffering from respiratory illnesses acquired through employment. The firm’s expert solicitors make the claims process simple and straightforward and offer free, no obligation, initial advice as well as arranging home visits across England and Wales.  Armed with the experience and specialist knowledge that is required for this complex area, Hugh James has helped thousands of people who have developed an illness as a result of their work. Our legal professionals are highly experienced and have been successfully handling disease and illness claims for over 50 years. Hugh James | Top 100 Full Service UK Law Firm

Hodge Jones & Allen Solicitors is one of the UK’s most progressive law firms, renowned for doing things differently and fighting injustice. For over 40 years’ the firm has been at the centre of numerous landmark legal cases that have helped and changed lives for so many people.  Committed to providing first class personal legal services, our services include: Civil Liberties & Human Rights, Criminal Defence, Dispute Resolution, Employment Law, Family Law, Financial Crime & Regulatory, Housing & Property, Medical Negligence, Mental Capacity, Personal Injury, Wills & Probate. Tel:  0808 239 9917   Email:          @hodgejonesallen

Regeneron and Sanofi have collaborated since 2007 to develop fully-human monoclonal antibodies for the treatment of serious diseases, including cancer. Together, they are committed to advancing therapies that make a difference for patients.

Societies at the Virtual BTOG 2021

BTOG extends invitations to various societies to exhibit at its annual conference – societies have not been charged to exhibit at BTOG 2021.

ALK Positive Lung Cancer (UK) is a registered charity established by patients and carers. We provide support and advocacy to improve the overall survival and quality of life of ALK-Positive lung cancer patients in the UK.


  • Have a Facebook group for ALK-positive patients and family which offers mutual support
  • Identify and locate ALK-positive patients through engagement with key healthcare professionals
  • Hold national meetings where ALK-positive patients can hear from and ask questions of experts
  • We liaise with decision makers e.g. NICE, DVLA, NHS and the medical profession to promote the best treatment for patients

Find out more at

The Asbestos Victims Support Groups’ Forum (UK) is a registered charity and an umbrella organisation for asbestos victims’ support groups in the UK.  Collectively we provide one voice for asbestos victims.   Our work We are a collective of support groups who join together to fight for a better future for victims of asbestos related diseases.  We campaign for improvements in benefits and for fairer compensation, raise money and fight for mesothelioma research, demand decent medical treatment, raise awareness of the dangers of asbestos and raise awareness to protect future generations from the dangers of asbestos.

EGFR Positive UK is a patient-led charity committed to providing information and support for EGFR mutation positive lung cancer patients and their families. We have an active community on Facebook where members across the UK share experiences of treatment, side effects and offer emotional support to one another. Patients learn about us through social media or referral from their oncology teams, in particular their clinical nurse specialists.   We are dedicated to supporting research as well as ensuring the patient’s voice is heard in all relevant arenas, working with partners across the lung cancer community such as NICE, the UKLCC and the pharmaceutical industry. We believe addressing questions which are meaningful to patients and that accommodate patients’ real-world experiences of living with an oncogene-driven lung cancer offers significant opportunities to deliver outcomes which will improve and extend lives.  We also work to raise awareness of EGFR mutation positive lung cancer, as well as lung cancer in general. At the beginning of May, we will launch a national campaign in partnership with ALK Positive UK and The Ruth Strauss Foundation which will focus on raising awareness of never-smoking lung cancer amongst primary healthcare professionals. Many of our members are younger, never-smokers.We know that anyone with lungs can get lung cancer.  Please get in touch if you would like further information about what we do.

Lung Cancer Nursing UK (LCNUK) – formerly the National Lung Cancer Forum for Nurses (NLCFN) -  is a Charitable Incorporated Organisation (CIO) which aims to advance health by providing support, professional development, peer networking and research opportunities for cancer nurse specialists involved in caring for people with lung cancer and mesothelioma.  Membership is open to any specialist nurse who spends more than 50% of their working week or clinical activities in caring for patients with lung cancer and or mesothelioma.

Mesothelioma UK is a national specialist resource centre, specifically for the asbestos-related cancer, mesothelioma.   The charity is dedicated to providing specialist mesothelioma information, support and education, and to improving care and treatment for all UK mesothelioma patients and their carers.  The charity integrates into NHS front line services to ensure specialist mesothelioma nursing is available at the point of need.   This is achieved through a growing network of specialist mesothelioma nurses, regionally based in NHS hospitals but funded by Mesothelioma UK.

The National Lung Cancer Audit (NLCA) was developed after it was found that lung cancer patients in the UK had worse outcomes than comparable countries that spend a similar amount of money on healthcare. The NLCA strives to raise standards across clinical teams to improve treatment and outcomes for patients with lung cancer.

Since 2004 the NLCA has collected data on patients with lung cancer to review the quality of lung cancer care, identify areas for improvement and reduce variation in practice. The NLCA produces several reports that summarise the analysis of the data collected.

Latest annual report

Roy Castle Lung Cancer Foundation - the only UK charity dedicated to lung cancer.

We have funded 36 research projects into early detection and patient experience of lung cancer, three Clinical Research Fellows and a lung health check pilot in Nottingham. Our campaigning work includes raising awareness, challenging misconceptions, and campaigning for better quality of life, we do everything we can to ensure everyone has an increased awareness of the disease and who it affects. And, for the people who have lung cancer, we ensure they live well with it.  We have a range of information materials (nine booklets, three factsheets and an information pack) which are available free of charge. Our Ask the Nurse service supports patients, carers and those with concerns about lung cancer via telephone, email and our online community. Demand for this service doubled with the arrival of Covid-19. Many of our patient/carer community were more isolated than usual throughout the pandemic and we therefore introduced a Keep in Touch service. This has proved invaluable to patients and will continue for the foreseeable future. We are excited to launch our Lung Cancer Connect project, designed to improve support to people affected by lung cancer by way of online and telephone support groups, digital resource library, patient navigation aid, support and mentoring service and online events.  Lung Cancer Connect will run alongside our existing support services and face-to-face services (when not affected by Covid-19 restrictions).  The charity also acts as Secretariat for the UK Lung Cancer and Mesothelioma Clinical Expert Group.

The UK Lung Cancer Coalition (UKLCC) is the UK’s largest multi-interest group in lung cancer. was set up in 2005 with the founding ambition of tackling poor survival outcomes - specifically to double five-year lung cancer survival by 2015, which was effectively achieved. Since then, it has pushed for a wide range of efforts to achieve a 5-year survival rate of 25 per cent by 2025. It has worked tirelessly with health professionals, NHS trusts, cancer networks, Royal Colleges and Government to help reduce the terrible death toll of lung cancer e.g., it was a major protagonist in lobbying NHS Trusts to submit data for the National Lung Cancer Audit (NLCA) to help drive up best-practice and standards.  The UKLCC has also published more than ten, ground-breaking, national reports. These include: 25 by 25: a ten-year strategy to improve lung cancer survival rates, Early Diagnosis Matters, Access Matters, Pathways Matter - the first report to review of uptake of the National Optimal Lung Cancer Pathway - and most recently, COVID-19 Matters, which identified the impact of the pandemic on services and outcomes, and highlighted changes the community could potentially adopt and adapt to help regain momentum in lung cancer going forward. A further report, mapping the ‘Route back to 25 by 25’ and restoration of services in a post COVID world, will be published later this year. To access the range of published UKLCC reports, visit

VJOncology is an independent, open-access video journal, providing trusted and up to date information to HCPs through innovative digital media – including video, podcasts, e-learning, editorial features and more. We rapidly publish the latest expert opinion from global medical congresses to improve the awareness and understanding of cancers.  To receive our latest news coverage of BTOG and updates in lung cancer, sign up to our newsletter here: